Related Experiment Videos
Experience with minimal complications in implanted catheters in children
M J Hockenberry1, W H Schultz, B Bennett
1Department of Pediatric Oncology, Duke University, Durham, North Carolina.
Insights
Implanted central venous catheters provide safe and effective venous access for pediatric patients undergoing chemotherapy or with hematologic disorders, showing minimal complications. This method improves infusion capabilities for various treatments.
Area of Science:
- Pediatric Oncology
- Vascular Access Devices
- Hematology
Background:
- Improved venous access is critical for pediatric patients requiring long-term treatments.
- Traditional central venous catheters can be associated with significant complication rates.
Purpose of the Study:
- To evaluate the safety and efficacy of percutaneously placed implanted central venous catheters in pediatric patients.
- To assess complication rates and functional duration of these devices.
Main Methods:
- Percutaneous placement of implanted central venous catheters in 82 pediatric patients (11 months to 24 years).
- Patients received treatment for cancer or chronic hematologic disorders.
- Data collected on catheter function duration and complications.
Main Results:
- Mean catheter function was 168 days (range 7-1,030 days), with 18,812 cumulative days of use.
- Complications were minimal, with only 5% of catheters requiring removal due to infection, infiltration, or tissue breakdown.
- Reduced complication rates were observed compared to other studies.
Conclusions:
- Implanted central venous catheters are safe and effective for pediatric patients with cancer or hematologic disorders.
- These devices facilitate chemotherapy, hyperalimentation, blood product, and other infusions.
- The catheters are safe for patients with hemostatic or host defense deficiencies.
Abstract:
Eighty-two patients, ranging in age from 11 months to 24 years, underwent the percutaneous placement of an implanted catheter in order to have improved venous access. Thirty-five patients (43%) were beginning chemotherapy for cancer, four (5%) had a chronic hematologic disorder, and the remaining 43 (52%) were on chemotherapy for cancer. The mean duration of catheter function was 168 days (range of 7-1,030 days), with a cumulative experience of 18,812 days of catheter use. Complications were minimal. Only four catheters (5%) required removal secondary to infection, infiltration, or tissue breakdown. Substantially reduced complication rates were observed as compared to other studies using implanted central venous catheters. Implanted central venous catheters were proven to be safe in patients with hematologic disorders. These catheters enhance the ability to infuse chemotherapy, hyperalimentation, blood products, anesthesia, and imaging solutions and are safe to use in patients with a hemostatic or host defense deficiency.